These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 33258389)
21. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Yang N; Chen T; Wang L; Liu R; Niu Y; Sun L; Yao B; Wang Y; Yang W; Liu Q; Tu K; Liu Z Theranostics; 2020; 10(13):5790-5801. PubMed ID: 32483419 [No Abstract] [Full Text] [Related]
22. UNC119 promoted cell growth and migration by Wnt/β-catenin signal and TGF-β/EMT signal pathway in hepatocellular carcinoma. Liu ZH; Zhang YF; Xu ZD; Z H L; Y F Z; Z D X J BUON; 2018; 23(6):1717-1724. PubMed ID: 30610799 [TBL] [Abstract][Full Text] [Related]
23. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma. Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875 [TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway. Li Y; Liu G; Li X; Dong H; Xiao W; Lu S Biochem Biophys Res Commun; 2018 Sep; 503(4):2826-2832. PubMed ID: 30115383 [TBL] [Abstract][Full Text] [Related]
25. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919 [TBL] [Abstract][Full Text] [Related]
26. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway. Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154 [TBL] [Abstract][Full Text] [Related]
27. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107 [TBL] [Abstract][Full Text] [Related]
28. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718 [TBL] [Abstract][Full Text] [Related]
29. SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition. Xu J; Li X; Yang H; Chang R; Kong C; Yang L Cancer; 2013 Jun; 119(12):2247-57. PubMed ID: 23564492 [TBL] [Abstract][Full Text] [Related]
30. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Xiao S; Chang RM; Yang MY; Lei X; Liu X; Gao WB; Xiao JL; Yang LY Hepatology; 2016 Apr; 63(4):1256-71. PubMed ID: 26698646 [TBL] [Abstract][Full Text] [Related]
31. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. Hou KZ; Fu ZQ; Gong H World J Gastroenterol; 2015 Jan; 21(2):475-83. PubMed ID: 25593462 [TBL] [Abstract][Full Text] [Related]
32. β-Arrestin1 is involved in hepatocellular carcinoma metastasis via extracellular signal-regulated kinase-mediated epithelial-mesenchymal transition. Xu X; Lei Y; Zhou H; Guo Y; Liu H; Jiang J; Yang Y; Wu B J Gastroenterol Hepatol; 2020 Dec; 35(12):2229-2240. PubMed ID: 32445259 [TBL] [Abstract][Full Text] [Related]
33. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816 [TBL] [Abstract][Full Text] [Related]
34. POU2F1 over-expression correlates with poor prognoses and promotes cell growth and epithelial-to-mesenchymal transition in hepatocellular carcinoma. Zhong Y; Huang H; Chen M; Huang J; Wu Q; Yan GR; Chen D Oncotarget; 2017 Jul; 8(27):44082-44095. PubMed ID: 28489585 [TBL] [Abstract][Full Text] [Related]
35. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway. Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743 [TBL] [Abstract][Full Text] [Related]
36. MiR-552 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression. Qu W; Wen X; Su K; Gou W J Cell Mol Med; 2019 Feb; 23(2):1541-1552. PubMed ID: 30597727 [TBL] [Abstract][Full Text] [Related]
37. Six2 is negatively correlated with prognosis and facilitates epithelial-mesenchymal transition via TGF-β/Smad signal pathway in hepatocellular carcinoma. Wan ZH; Ma YH; Jiang TY; Lin YK; Shi YY; Tan YX; Dong LW; Wang HY Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):525-531. PubMed ID: 31564506 [TBL] [Abstract][Full Text] [Related]
38. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Liu X; Ou H; Xiang L; Li X; Huang Y; Yang D Oncotarget; 2017 Feb; 8(6):10510-10522. PubMed ID: 28060737 [TBL] [Abstract][Full Text] [Related]
39. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858 [TBL] [Abstract][Full Text] [Related]
40. KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. Han J; Wang F; Lan Y; Wang J; Nie C; Liang Y; Song R; Zheng T; Pan S; Pei T; Xie C; Yang G; Liu X; Zhu M; Wang Y; Liu Y; Meng F; Cui Y; Zhang B; Liu Y; Meng X; Zhang J; Liu L Oncogene; 2019 Jan; 38(3):406-420. PubMed ID: 30115976 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]